SSB and synovial sarcoma: Future studies will also focus on assessing the utility of this panel of miRNA in identifying SS patients as well as exploring the utility of these miRNA in longitudinal disease progression in combination with existing blood-based biomarkers such as anti-La and anti-Ro antibodies and others.